ArticleAmerican journal of translational research2009
Neuroendocrine differentiation in prostate cancer.
Article in American journal of translational research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Endocrine and paracrine characteristics of neuroendocrine prostate cancer.Frontiers in endocrinology · 2022Pooled it
- Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.Asian journal of andrologyPooled it
- Clinicopathological Profiles and Outcomes of Low vs High PSA Metastatic Prostate Adenocarcinoma: a Retrospective Study from a Single Tertiary Care Centre in South India.Indian journal of surgical oncology · 2025Article
- Castration-Resistant Prostate Cancer Presenting as Bulky Lymphadenopathy: A Case without Bone Metastasis.The American journal of case reports · 2025Article
- Stromal-derived MAOB promotes prostate cancer growth and progression.Science advances · 2024Article
- BeyondMolecular therapy oncolytics · 2023Review
- Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.The journal of pathology. Clinical research · 2023Article
- Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy.Biomedicines · 2023Review
- Neuroendocrine Differentiation of Lung Cancer Cells Impairs the Activation of Antitumor Cytotoxic Responses in Mice.International journal of molecular sciences · 2023Article
- Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.Cell death & disease · 2022Article
- Imaging of Neuroendocrine Prostatic Carcinoma.Cancers · 2021Review
- Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.Precision clinical medicine · 2021Review
- De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.Medical oncology (Northwood, London, England) · 2021Article
- Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?Cancers · 2021Review
- Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.Frontiers in pharmacology · 2021Article
- Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1.Science translational medicine · 2020Article
- The Role of Lysosome-associated Membrane Protein 2 in Prostate Cancer Chemopreventive Mechanisms of Sulforaphane.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.Oncogenesis · 2020Article
- Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.International journal of molecular sciences · 2020Article
- MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As any organ in the body human prostate is composed of many different types of cells as well as extracellular components. During prostate development, reciprocal cellular interactions between stromal cells and prostate epithelial cells ultimately lead to the development of a mature prostate. Normal prostate is composed of repeating cellular units that contain stromal and epithelial compartments. The epithelial compartment contains luminal epithelial cells, basal cells and a minor component of neuroendocrine cells whose function may be to regulate the growth, differentiation and secretory function of the prostate gland. Neuroendocrine cells are also evident in prostate cancer and numerous studies showed that its number increases in high grade and high stage tumors, particularly in hormonally treated and hormone-refractory (androgen-independent) prostate cancer. Although androgen withdrawal reduces the secretion of the andromedins from the prostate stromal cells that are critical for the survival for prostate epithelial cells, there is clear evidence that androgen receptor is also required for the tumorigenesis of human prostate cancer, and therefore androgen deprivation therapy likely works through inhibition of androgen receptor in the prostate epithelium. Because neuroendocrine cells lack androgen receptor and are likely androgen-independent, it is conceivable that hormonal therapy for advanced/metastatic prostate cancer, which consists of inhibiting androgen production and/or blocking androgen receptor function, will not eliminate neuroendocrine cancer cells. Instead, these cells may be enriched after the therapy and they may establish paracrine networks to stimulate androgen-independent proliferation of prostate cancer, leading to tumor recurrence. In this article, we will review the known functions of the neuroendocrine cells in prostate cancer, including stimulation of cancer proliferation and invasion, apoptosis resistance and angiogenesis as well as molecular pathways involved in neuroendocrine differentiation.
Indexed as
Identifiers
19956427PMC2776313W1587021131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.